Systemic overexpression of SQSTM1/p62 accelerates disease onset in a SOD1H46R_ expressing ALS mouse model

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by a selective loss of upper and lower motor neurons. Recent studies have shown that mutations in SQSTM1 are linked to ALS. SQSTM1 encodes SQSTM1/p62 that regulates not only autophagy via the association with MAP1LC3/LC3 and ubiquitinated proteins but also the KEAP1-NFE2L2/Nrf2 anti-oxidative stress pathway by interacting with KEAP1. Previously, we have demonstrated that loss of SQSTM1 exacerbates disease phenotypes in a SOD1H46R-expressing ALS mouse model. To clarify the effects of SQSTM1 overexpression in this model, we generated SQSTM1 and SOD1H46R double-transgenic (SQSTM1; SOD1H46R) mice. SQSTM1; SOD1H46R mice exhibited earlier disease onset and shorter lifespan than did SOD1H46R mice. Conversely, disease progression after the onset rather slightly but significantly slowed in SQSTM1; SOD1H46R mice. However, there were observable differences neither in the number of Nissl positive neurons nor in the distribution of ubiquitin-positive and/or SQSTM1-positive aggregates between SOD1H46R and SQSTM1; SOD1H46R mice. It was noted that these protein aggregates were mainly observed in neuropil, and partly localized to astrocytes and/or microglia, but not to MAP2-positive neuronal cell bodies and dendrites at the end-stage of disease. Nonetheless, the biochemically-detectable insoluble SQSTM1 and poly-ubiquitinated proteins were significantly and progressively increased in the spinal cord of SQSTM1; SOD1H46R mice compared to SOD1H46R mice. These results suggest that overexpression of SQSTM1 in SOD1H46R mice accelerates disease onset by compromising the protein degradation pathways.